Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mylan pharmaceuticals limited - rasagiline tartrate - marda ta 'parkinson - mediċini kontra l-parkinson - rasagiline mylan huwa indikat għat-trattament ta ' l-idiopathic parkinson's marda (pd) bħala monotherapy (mingħajr ticlopidine hydrochloride) jew bħala terapija frozen (b ' ticlopidine hydrochloride) fil-pazjenti bl-għan ta ' l-oxxillazzjonijiet ta ' doża.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mylan pharmaceuticals limited - anagrelide hydrochloride - tromboċitemja, essenzjali - aġenti antineoplastiċi - anagrelide huwa indikat għat-tnaqqis tal-għadd għoli tal-plejtlets f'mill-riskju tromboċitemja essenzjali (et) tal-pazjenti li jkunu intolleranti għall it-terapija attwali tagħhom jew li l-għadd għoli tal-plejtlets tagħhom ma jitnaqqasx għal-livell aċċettabbli bit-terapija attwali tagħhom. an at-risk patientan at-risk essential thrombocythaemia patient is defined by one or more of the following features:>60 years of age ora platelet count >1,000 x 10⁹/l ora history of thrombo-haemorrhagic events.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - pemetrexed - carcinoma, non-small-cell lung; mesothelioma - folic acid analogues, antineoplastic agents - mesoteljoma plewrali malinna pemetrexed medac flimkien ma ' cisplatin huwa indikat għat-trattament tal-kimoterapija naïve pazjenti b'mesoteljoma plewrali malinna u li ma jistax jitneħħa. taċ-ċelluli mhux żgħar tal-pulmun il-kanċer pemetrexed medac flimkien ma 'cisplatin huwa indikat għat-trattament tal-ewwel linja ta' pazjenti b'lokalment avvanzat jew metastatiku taċ-ċelluli mhux żgħar tal-pulmun il-kanċer l-oħra mill-aktar istoloġija ta ' ċelluli skwamużi. pemetrexed medac huwa indikat bħala monoterapija għall-kura ta 'manteniment ta lokalment avvanzat jew metastatiku taċ-ċelluli mhux żgħar tal-pulmun il-kanċer l-oħra mill-aktar istoloġija ta' ċelluli skwamużi fir-pazjenti li l-marda tagħhom ma jkunx hemm progress immedjatament wara ibbażat fuq il-platinu ' kimoterapija. pemetrexed medac huwa indikat bħala monoterapija għall-tieni linja ta 'trattament ta' pazjenti b'lokalment avvanzat jew metastatiku taċ-ċelluli mhux żgħar tal-pulmun il-kanċer l-oħra mill-aktar istoloġija ta ' ċelluli skwamużi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

accord healthcare s.l.u. - abiraterone acetate - neoplasmi prostatiċi - terapija endokrinali - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

immedica pharma ab - glycerol phenylbutyrate - disturbi taċ-Ċiklu ta 'l-urea, inborn - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - ravicti huwa indikat għall-użu bħala terapija aġġuntiva għall-kroniku tal-ġestjoni ta 'pazjenti bil-urea disturbi fiċ-ċiklu (ucds) inklużi n-nuqqasijiet tal-carbamoyl phosphate-synthase-i (cps), ornithine carbamoyltransferase (otc), argininosuccinate synthetase (ass), argininosuccinate lyase (asl), arginase i (arg) u ornithine translocase defiċjenza hyperornithinaemia-iperammonemija homocitrullinuria sindromu (hhh) li ma jistgħux ikunu ġestiti mill-restrizzjoni ta' proteini tad-dieta u/jew l-aċidu amminiku supplimentazzjoni waħdu. ravicti għandhom jiġu użati mal-restrizzjoni ta ' proteini tad-dieta u, f'xi każijiet, supplimenti tad-dieta (e. , amino acids essenzjali, arginine, citrulline, supplimenti ta 'kaloriji mingħajr proteini).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

zoetis belgium sa - synthetic peptide analogue of gnrf conjugated to diptheria toxoid - immunoloġiċi għal suidae - male pigs (from 8 weeks of age); female pigs (from 14 weeks of age) - male pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of testicular function. for use as an alternative to physical castration for the reduction of boar taint caused by the key boar taint compound androstenone, in entire male pigs following the onset of puberty. kontributur ewlieni ieħor għall-tifqigħa tal-ħanżir, skatole, jista 'jitnaqqas ukoll bħala effett indirett. mġieba aggressiva u sesswali (immuntar) huma wkoll imnaqqsa. female pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of ovarian function (suppression of oestrus) in order to reduce the incidence of unwanted pregnancies in gilts intended for slaughter, and to reduce the associated sexual behaviour (standing oestrus).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

cycle pharmaceuticals (europe) ltd - nitisinone - tyrosinemias - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - it-trattament tal-pazjenti adulti u pedjatriċi b'dijanjosi kkonfermata ta 'tirosinemia ereditarja ta' tip 1 (ht-1) flimkien ma 'restrizzjoni tad-dieta ta' tyrosine u phenylalanine.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sandoz pharmaceuticals d.d. - zoledronic acid - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - drogi għat-trattament ta 'mard tal-għadam - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture, including those with a recent low-trauma hip fracture. trattament ta ' osteoporożi assoċjat ma sistemiku fit-tul terapija bi glukokortikojdi fil-nisa wara l-menopawża u f'irġiel f'riskju akbar ta'ksur. it-trattament tal-marda ta'paget ta ' l-għadam.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

immedica pharma ab - sodium phenylbutyrate - ornithine carbamoyltransferase deficiency disease; citrullinemia; carbamoyl-phosphate synthase i deficiency disease - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - ammonaps hu indikat bħala terapija aġġuntiva fit-kroniku tal-ġestjoni tal-urea disturbi fiċ-ċiklu, li jinvolvi defiċjenzi tal-carbamylphosphate synthetase, ornithine transcarbamylase orargininosuccinate synthetase. huwa indikat fil-pazjenti kollha b'neonatal-onset presentation (tlesti l-enżima n-nuqqasijiet li jidhru fl-ewwel 28 ġurnata tal-ħajja). huwa indikat ukoll f'pazjenti bil-marda li ħarġet tard(nuqqasijiet parzjali fl-enżimi, li jidhru wara l-ewwel xahar tal-ħajja) li għandhom storja ta ' enċefalopatija iperammonemika.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

eurocept international b. v. - sodium phenylbutyrate - carbamoyl-fosfat synthase i marda defiċjenza - varji ta'l-apparat alimentari u tal-metaboliżmu-prodotti - it-trattament kroniku tal-ġestjoni tal-urea-disturbi fiċ-ċiklu.